SureTrader SureTrader SureTrader
Home > Boards > US OTC > Miscellaneous >

InMed Pharmaceuticals Inc. (IMLFF)

IMLFF RSS Feed
Add IMLFF Price Alert      Hide Sticky   Hide Intro
Moderator: stockman69, lesgetrich
Search This Board:
Last Post: 1/20/2017 4:53:21 PM - Followers: 112 - Board type: Free - Posts Today: 20



 

InMed Pharmaceuticals is a drug discovery and development company uniquely
focused on the therapeutic potential of cannabinoids.

 

DEVELOPING NOVEL THERAPIES THROUGH RESEARCH AND DEVELOPMENT

InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company that specializes in developing therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.


Corporate Presentation
https://www.inmedpharma.com/site/assets/files/1343/jan-cp-2017-2.pdf
 

OVERVIEW

InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

InMed is utilizing its proprietary bioinformatics assessment tool to identify bioactive compounds within the cannabis plant that have the potential to have physiological impacts on specific diseases. The goal is to identify new drug candidates that optimize therapeutic benefit while limiting adverse effects.

InMed’s proprietary in silico drug/disease bioinformatics assessment tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company.
 

MANAGEMENT

Eric A. Adams

President & CEO

Mr. Adams is a seasoned biopharmaceutical executive with over 25 years’ experience in company and capital formation, global market development, mergers & acquisitions, licensing and corporate governance. Mr. Adams previously served as CEO at enGene Inc., which he led from a nascent start-up to becoming a venture capital-backed leader in gene therapy. Prior to enGene, he held key senior roles in global market development with QLT Inc. (Vancouver), Advanced Tissues Science Inc. (La Jolla), Abbott Laboratories (Chicago), and Fresenius AG (Germany). Mr. Adams is well regarded in the Canadian biotech industry for his service as a strategic advisor to a number of early-stage biotech companies, as a previous Chairman of BIOTECanada’s Emerging Company Advisory Board and for his extensive generosity in mentoring biotech entrepreneurs.

He is a dual citizen of Canada and the United States and holds a Masters of International Business from the University of South Carolina and a Bachelors in Chemistry from the University of Southern Indiana.

Dr. Sazzad Hossain, Ph.D., M.Sc.

Chief Scientific Officer

Dr. Hossain has more than 20 years of academic and industrial experience in new drug discovery, natural health product development. He was Group Leader and Senior Scientist at Biotechnology Research Institute of National Research Council Canada, Government of Canada’s prime biotechnology research organization where he set up pharmacology laboratory to evaluate safety and efficacy of new drugs under development in the areas of cancer, cardiovascular and ocular diseases. Prior to joining the National Research Council Canada, he was at Xenon Pharmaceuticals in Vancouver, B.C, where was Associate Director of Pharmacology and led pharmacology teams targeting pain, inflammation and cardiovascular diseases. Dr. Hossain received his PhD in Biology from Moscow State Academy of Veterinary Medicine & Biotechnology and received post-doctoral training in the Department of Nutritional Science and Department of Medical Genetics of University of British Columbia. He was associate professor of pharmacology at Federal University of Minas Gerais, Brazil between 1988 -1996. He is the author of more than 40 peer-reviewed papers, primarily in the pharmacology, genetics and nutritional sciences.

Dr. Ado Muhammed, MD, DPM, MFPM

Chief Medical Officer

Dr. Muhammed is a proven leader in the development of cannabinoid therapies, having played a strategic role in the clinical development, R&D, and commercialization of these specialty drugs. His previous position was Associate Medical Director at GW Pharmaceuticals, a UK-based Pharmaceutical Company specializing in the development of cannabinoid based prescription medicines. In this role and others at GW Pharmaceuticals, Dr. Muhammed was involved in the advanced delivery of core clinical research and was involved in key decision-making regarding R&D and product commercialization. Dr. Muhammed’s received his MD at Ahmadu Bello University followed by an MSc in Orthopaedics at University College London. Dr. Muhammed achieved a DipPharMed in Pharmaceutical Medicine at University of Wales in Cardiff followed by an MBA in Business Administration at the University of Leicester. He is Member, Faculty of Pharmaceutical Medicine (Royal College of Physicians of England), the British Association of Pharmaceutical Physicians and the International Society for Pharmacovigilance.

Alexandra D.J. Mancini, M.Sc.

Senior Vice President, Clinical and Regulatory Affairs.

Ms. Mancini has over 30 years’ of global biopharmaceutical R&D experience with a particular emphasis on clinical development and regulatory affairs. Ms. Mancini has been an executive with several biotech companies, verseeing a wide range of drug development activities. As Sr. VP of Clinical & Regulatory Affairs at Sirius Genomics, her role included identifying and managing external resources for medical expertise in sepsis; linical data management; and statistical theory, programming and analyses. While at INEX Pharmaceuticals as Sr. VP of Clinical & Regulatory Affairs, Ms. Mancini oversaw Clinical Research, Medical Affairs, Clinical Data Management, Medical Writing, Regulatory Affairs, and Quality Assurance for oncology. She served as VP of Regulatory Affairs at QLT Inc. for oncology and ocular diseases, playing a significant role in the development of VISUDYNER from the preclinical stage through to its approval as the first drug for age-related macular degeneration. While at QLT, Ms. Mancini also led the regulatory approval process for the anticancer drug PHOTOFRINR and its associated medical devices, the first drug-device combination product approved by the US Food and Drug Administration. Ms. Mancini has led the data analysis and assimilation, writing, submission and subsequent defense of drug submissions to regulatory agencies around the world, leading to several drug approvals and label extensions.

Ms. Mancini holds a Master of Science degree from the University of Toronto. She is also a Visiting Lecturer at the Segal Graduate School of Business, Simon Fraser University.

Chris Bogart

SVP, Corporate Strategy & Investor Relations

Mr. Bogart is a co-founder of InMed Pharmaceuticals and currently serves as the SVP of Corporate Strategy and Investor Relations. Mr. Bogart has over 18 years in international business development, strategic decision-making and planning. Mr. Bogart is a seasoned capital markets professional with an extensive background in equity financings and strategic communications for publicly traded companies in a senior management role. He has planned, executed and maintained Investor Relations & Communication initiatives in Canada, United States and Europe.

Jeff Charpentier

CFO, Chief Financial Officer

Chief Financial Officer

Mr. Charpentier is a veteran of the biopharmaceutical industry with over 25 years of experience. Jeff has held a series of senior financial roles at several public and private companies in the pharmaceutical and technology sectors where he led multiple equity financings, raising in excess of $150M and concluded a number of corporate partnering/product sale transactions. Jeff previously served as CFO for Lifebank Corp. (through to successful company sale in 2012), Inex Pharmaceuticals Corporation (now Arbutus Biopharma Corp.), and Chromos Molecular Systems Inc. Jeff has a Bachelor of Commerce degree from the University of British Columbia and is a member of the Chartered Professional Accountants of BC.


 

PIPELINE

InMed Pharmaceuticals is currently developing two products in its drug pipeline: INM-750, for the treatment of Epidermolysis Bullosa, and INM-085, for the treatment of Glaucoma.


 

Epidermolysis Bullosa (EB) is group of inherited connective tissue diseases that share a common manifestation of extremely fragile skin that blisters or tears easily from friction or trauma. Internal organs and bodily systems can also be affected by EB. It is a result in a defect of anchoring between the dermis and epidermis cause most frequently by the absence of certain keratins (or, proteins) in the skin. EB is an orphan disease with no currently approved treatments and has a significant unmet medical need. INM-750 will potentially be the first therapy designed and developed specifically to modulate disease activity and to alleviate symptoms in EB.

INM-750 includes multiple cannabinoids as the active ingredients:

The cannabinoids included in INM-750 were selected to modulate keratin levels in patients with EB with the expectation of having a disease modulating effect
A secondary consideration in selection of the cannabinoids was addressing symptoms of EB such as inflammation, wound healing, skin regeneration, itching, and pain
INM-750 is being developed for topical application, designed to maximize penetration of the cannabinoids to the epidermal / dermal junction in the skin.

 

INM-085

Glaucoma is a group of eye disorders which result in damage of the optic nerve. The damage is most often caused by an abnormally high pressure in the eye and is one of the leading causes of blindness in the developed world.

INM-085 will be the first ever glaucoma treatment developed that is a multi-target, multi-mechanism of action therapy, utilizing multiple cannabinoids for optimal efficacy. The cannabinoids in INM-085 have been selected to reduce the elevated intra-ocular pressure (IOP) in the affected eyes and provide neuroprotection for the retinal ganglion cells (RGCs) and other optic nerve tissues.

INM-085 is designed as a topical formulation to be administered directly to the eye. The formulation that has been designed by InMed is a proprietary polymer-based formulation to facilitate absorption of the cannabinoids into the eye while also being well tolerated by the patients. We envision a once-a-day application, at bedtime, to deliver effective dose levels of INM-085.

 

BIOINFORMATICS

Bioinformatics: Proprietary Drug / Disease Targeting Tool

InMed’s has developed a computer-based program to assist in the identification of novel cannabinoids using: (i) comprehensive algorithms to integrate data from numerous bioinformatics databases, (ii) a database on the structure of currently approved pharmaceutical products, and (iii) an extensive database on over 90 individual cannabinoid drugs found in cannabis.

InMed’s data included in its bioinformatics assessment tool are derived from both public and propriety based sources, and include information on:
Protein-Protein interactions
Gene Regulation
Epigenetic modification
Cell signal networks, and
Metabolomics








InMed uses processes called “random walk algorithms” and “guilt by association” to establish gene and protein-protein interaction networks to identify multi-target based approaches for therapy development for specific diseases.By using its comprehensive pharmaceutical and cannabinoid structures database, and by creating associations between approved pharmaceuticals (whose pharmacodynamics effects are well characterized) and cannabinoids with similar structures, InMed identifies active cannabinoids to act on above mentioned genes and proteins.Once a series of potentially active cannabinoids are identified for a specific disease target, InMed will test and confirm their activity in biological systems with 
in vitro and in vivo
 experimentation.This type of bioinformatics assessment, as a general approach, represents significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.

 

AREAS OF RESEARCH

Proposed Targets to Develop Drugs From Cannabis and Other Botanical Sources

Dermatology

Epidermolysis Bullosa
Pachyonychia Congenital
Epidermolytic Ichthyosis
Pemphigus Vulgaris

Ocular

Glaucoma
 
Ocular Allergies

Pain and Inflammation

Orofacial Pain
 
Rheumatoid Arthritis

CNS

Huntington’s Disease

Epilepsy
Anti-anxiety

Respiratory

COPD

Asthma
Rhinitis

Metabolic Disease

Diabetes

Obesity
Metabolic Syndrome
 

R & D PARTNERSHIPS

University of British Columbia
Department of Chemical & Biological Engineering
Vancouver Campus
2360 East Mall
Vancouver, BC Canada V6T 1Z3

Department of Pharmaceutical Sciences
Vancouver Campus
2405 Westbrook Mall
Vancouver, BC, Canada V6T 1Z3

University of Debrecen
Research Center for Molecular Medicine, Department of Physiology
1H-4032 Debrecen, Nagyerdei krt. 98
Hungary


 

2017




    •  

CAPITAL STRUCTURE

Cap Structure (as of Tue Jan, 1, 2017)
Issued & Outstanding 93.1 Million
Warrants 14.1 Million
Options 14.7 Million
Fully-Diluted 121.9 Million
  •  
 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IMLFF
Current Price
Volume:
Bid Ask Day's Range
SureTrader
IMLFF News: InMed Engages Peter Mountford as Strategic Advisor 05/05/2015 04:00:00 AM
IMLFF News: InMed Pharmaceuticals Qualifies for Electronic Trading in the U.S. 04/30/2015 11:00:00 AM
IMLFF News: InMed Awarded Grant for Proprietary Nanoparticle-Based Delivery System for Glaucoma Therapy 04/15/2015 06:00:00 AM
IMLFF News: InMed Receives Exemption Status from Health Canada 03/23/2015 08:00:00 AM
IMLFF News: InMed Forms Strategic Collaboration to Develop Novel Phytocannabinoid Therapies for Ocular Allergies 03/10/2015 11:00:00 AM
PostSubject
#1259  Sticky Note Interview with InMed CEO Eric Adams on company goals lesgetrich 12/22/16 10:57:01 PM
#1631   nice to be green on a Friday, strong stockman69 01/20/17 04:53:21 PM
#1630   Nice accumulation!!!! Next week we rock$$$ TooYoungToDie 01/20/17 03:49:50 PM
#1629   Loading zone here budfoxhub 01/20/17 02:41:37 PM
#1628   Crazy dip there wow, bounced back really nice stockman69 01/20/17 01:47:13 PM
#1627   InMedPharma -- califax 01/20/17 01:30:21 PM
#1626   Should see a nice push into power hour budfoxhub 01/20/17 01:14:25 PM
#1625   Thin here to .40's! budfoxhub 01/20/17 01:12:14 PM
#1624   Check out $IMLFF on Barchart Opinion, strong easymoneylucy 01/20/17 01:01:26 PM
#1623   Big private placement announced! stockman69 01/20/17 12:40:01 PM
#1622   FYI might wanna look at Standard Graphite SGH Bobin 01/20/17 12:36:07 PM
#1621   looking for .50+ by next week!! chart is stockman69 01/20/17 11:50:43 AM
#1620   Nice move today stockman69 01/20/17 11:49:54 AM
#1619   Trader's Cheat Sheet on $IMLFF: easymoneylucy 01/20/17 11:42:05 AM
#1618   And lots of green volume which is what Robertscott 01/20/17 11:34:54 AM
#1617   Volume is looking good today and green heading Cabroncita 01/20/17 11:23:31 AM
#1616   $IMLFF Technical Analysis easymoneylucy 01/20/17 10:10:17 AM
#1615   strong start, nice accumulation at .32 this AM stockman69 01/20/17 09:47:16 AM
#1614   $IMLFF Pipeline INM-075 and INM-085 easymoneylucy 01/20/17 09:32:55 AM
#1613   Good morning $IMLFF - awesome week here, looking stockman69 01/20/17 08:08:42 AM
#1612   Good morning all! Looking for a strong Cabroncita 01/20/17 07:55:44 AM
#1611   Inmed Pharmaceuticals Inc. (IMLFF) currently has a 14 Bobin 01/19/17 05:32:50 PM
#1610   .3218 green close coming here! budfoxhub 01/19/17 03:49:40 PM
#1609   closing in on 1 milly in volume as stockman69 01/19/17 02:53:23 PM
#1608   this and my other big winner $LXRP, couple stockman69 01/19/17 12:48:14 PM
#1607   One of the few green weed tickers today... starkd748 01/19/17 12:39:48 PM
#1606   Watch the $IMLFF [Inmed Pharmaceuticals] CEO Eric Adams stockman69 01/19/17 12:35:39 PM
#1605   Huge private placement closed for $IMLFF! stockman69 01/19/17 11:28:07 AM
#1604   OLD news from last friday Bobin 01/19/17 11:13:03 AM
#1603   The warrants have been exercised are are no Bobin 01/19/17 11:10:07 AM
#1602   Read this $IMLFF Corporate Presentation (PDF), Jan 2017 easymoneylucy 01/19/17 10:22:03 AM
#1601   RSI holding the power zone here: budfoxhub 01/19/17 10:10:52 AM
#1600   $IMLFF's Capital Structure is THIN, updated a/o Jan easymoneylucy 01/19/17 10:04:33 AM
#1599   It does look undervalued to me! Volume Cabroncita 01/19/17 09:47:19 AM
#1598   $IMLFF mkt cap under $30M, looks undervalued here stockman69 01/19/17 09:38:07 AM
#1597   $IMLFF in the green early this AM on news! stockman69 01/19/17 09:37:33 AM
#1596   More big news for $IMLFF! stockman69 01/19/17 09:37:22 AM
#1595   IMLFF News! InMed Pharma Appoints Eli Lilly Finance TPX 01/19/17 09:36:13 AM
#1594   January 19, 2017 09:00 ET rosie10 01/19/17 09:29:13 AM
#1593   January 19, 2017 09:00 ET rosie10 01/19/17 09:26:44 AM
#1592   Visit this link for $IMLFF Investors Overview: easymoneylucy 01/19/17 09:23:28 AM
#1591   Question: what happens to Mettrum stocks and price SVX95 01/19/17 08:24:23 AM
#1590   Good morning all! Looking for a strong Cabroncita 01/19/17 07:25:44 AM
#1589   Cool not much like longer....I'm not selling anyway starkd748 01/18/17 04:12:09 PM
#1588   All the warrants exercised as of Jan 24. Bobin 01/18/17 04:02:49 PM
#1587   U sell yet lol u know they stiil starkd748 01/18/17 03:51:04 PM
#1586   In @ .33 $IMLFF r1aviator 01/18/17 02:08:23 PM
#1585   Craig Schneider OUT as Director at InMed. Hip Bobin 01/18/17 01:44:54 PM
#1583   InMed (OTCQB: IMLFF) CEO Discusses R&D Pipeline on stockman69 01/18/17 01:30:13 PM
#1580   Better load up now @ .34 all cheapees ALL-IN888 01/18/17 01:11:13 PM
#1579   .32 nice support here budfoxhub 01/18/17 01:09:19 PM
PostSubject